| USWorld

Larger text Larger text Smaller text Smaller text | Order Photo Reprints

FDA grants approval for multiple sclerosis medication

Email Newsletters

Sign up for one of our email newsletters.

Daily Photo Galleries

By The Los Angeles Times
Thursday, March 28, 2013, 6:33 p.m.

WASHINGTON — An oral medication for multiple sclerosis has won the Food and Drug Administration's marketing approval and is to become available almost immediately to patients suffering from the debilitating auto-immune disease.

Tecfidera is the commercial name for dimethyl fumarate, a capsule that won the FDA's blessing this week as a treatment for relapsing MS, a degenerative brain disorder that can impair mobility, sensation and thinking.

In clinical trial evidence submitted to the FDA by Biogen Idec of Weston, Mass., the medication's maker, Tecfidera reduced the proportion of patients who relapsed when compared with a sham medication. In one of those trials, subjects taking Tecfidera showed less progression of the disease compared with those on a placebo. And both trials found that those taking Tecfidera twice daily developed fewer MS-related lesions in the brain.

The medication was formerly known as BG-12.

Those findings held whether patients had newly diagnosed multiple sclerosis or had their multiple sclerosis progress over some years, said Dr. Robert M. Fox, medical director of the Mellen Center for Multiple Sclerosis at the Cleveland Clinic, in a statement issued by Biogen Idec. Fox serves as a paid adviser to the firm and was lead investigator in one of the Tecfidera's earliest trials.

Common side effects of Tecfidera are flushing and gastrointestinal events, including nausea, diarrhea and vomiting. And though no increased rate of infections were noted in those taking Tecfidera in clinical trials, the medication may lower white blood counts and increase infection risk, the FDA said.

Subscribe today! Click here for our subscription offers.



Show commenting policy

Most-Read Nation

  1. Obama signs $607B Defense bill but blasts GOP limits for Gitmo
  2. ‘Crisis mode’ near at U.S.-Mexico line as nearly 5,000 children try to cross border in October
  3. Obama: No credible intelligence about terror plot against US
  4. Peanut glut poses hefty bailout tab for taxpayers
  5. Los Angeles-based water agency’s land buy rattles California farmers
  6. New Hampshire cancer patient gets permission to travel to Maine for medical pot
  7. Barrier nears completion in Indiana marsh to keep Asian carp from Great Lakes
  8. Foreign policy expert: Obama administration should create Syria safe areas
  9. Self-driving vehicles closer to getting green light as feds ease stance
  10. Girls outperform boys in variety of subjects, international survey shows
  11. Feds tell railroads they must meet deadlines for lifesaving technology